Genomic and Immunologic Correlates of Immunotherapy Response and Resistance via Longitudinal Tumor and Extracellular Vesicle (EV) Analysis
Abstract
One of the most promising recent therapeutic avenues has been cancer immunotherapy: boosting the immune system or training it against tumor antigens. However, only a fraction of patients receive durable clinical benefits from these therapies. There is a pressing need to identify factors predictive of clinical response to help make patient-specific treatment choices, understand the mechanisms of both de novo and acquired immunotherapy resistance, and nominate new therapeutic targets for combination therapy. We are undertaking multi-level analysis of longitudinal patient tumor samples in parallel with peripheral blood-derived extracellular vesicle (EV) RNA expression in patients undergoing checkpoint blockade therapy. We hypothesize that blood-based analysis will allow us to interrogate multiple tumor sites simultaneously, offering a more broad-based analysis of the tumor and immune landscape than tumor analysis alone. Additionally, tissue-of-origin analysis from EV transcripts during treatment will allow us to gain a comprehensive understanding of changes in the tumor microenvironment during checkpoint blockade immunotherapy.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2022
- Accession Number
- AD1192592
Entities
People
- Genevieve Boland
Organizations
- Massachusetts General Hospital